ROSSARI Rossari Biotech Q3 FY26 results (Oct–Dec 2025) and concall
Rossari Biotech Limited reported a healthy 13% year-on-year revenue growth to Rs. 581.7 crore in Q3 FY26, driven by strong performance across all segments and international markets. However, consolidated EBITDA margin stood at 11.8%, impacted by strategic investments in capacity expansion, new product development, and the implementation of new labor codes. The company is focused on improving profitability, particularly by addressing the underperforming B2C segment and leveraging new capacities, including a planned greenfield facility in KSA.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 22.6%, net profit up 0.0% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|
| Revenue | 368 | 427 | 366 | 420 | 451 +23% |
| EBITDA | 50 | 52 | 44 | 50 | 50 +0% |
| Net profit | 31 | 32 | 26 | 31 | 31 +0% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
